Cannabis Extracts Producer PharmaCielo Narrows Loss, Cuts Expenses In Q3, CEO Projects Higher Profitability
Cannabis Extracts Producer PharmaCielo Narrows Loss, Cuts Expenses In Q3, CEO Projects Higher Profitability
PharmaCielo Ltd. (TSXV:PCLO) (OTCQX:PCLOF) the Canadian parent of Colombia's cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., announced its financial results on Wednesday for the third quarter ended Sept. 30, 2023.
哥倫比亞種植商兼乾花和藥用級大麻提取物生產商Pharmacielo Ltd.（多倫多證券交易所股票代碼：PCLO）（OTCQX: PCLOF）週三公佈了截至2023年9月30日的第三季度財務業績。
The company narrowed its net loss and selling, general and administrative expenses significantly year-over-year as well as an adjusted EBITDA loss, the report showed.
報告顯示，該公司的淨虧損和銷售、一般和管理費用同比大幅縮小，調整後的息稅折舊攤銷前利潤虧損也大幅縮小。
"Our team has built a focused and lean organization over the past twelve months, and effectively re-positioned the product portfolio on higher margin products," Marc Lustig, chairman and CEO said. "With total SG&A expenses down over 40% from Q3 of last year, and no meaningful capital expenditures necessary to get to full commercial scale, we are even better placed to generate higher profitability and cash flows as our sales efforts pay off."
董事長兼首席執行官馬克·盧斯蒂格說：“在過去的十二個月中，我們的團隊建立了一個專注而精益的組織，並在利潤率更高的產品上有效地重新定位了產品組合。”“銷售和收購總支出比去年第三季度下降了40％以上，而且無需進行任何有意義的資本支出即可實現全面商業規模，隨着銷售工作的回報，我們更有能力創造更高的盈利能力和現金流。”
Q3 2023 Financial Results
2023 年第三季度財務業績
- Total revenue amounted to CA$351,688 ($258,777), down from CA$475,323 in the prior year's period.
- Gross loss totaled CA$349,187, up from $305,850 gross loss in the same quarter of 2022.
- Total selling, general, and administrative expenses amounted to roughly CA$2 million, down from CA$3.4 million in the corresponding period of last year.
- Net loss for the period totaled CA$2.8 million, down from CA$5.2 million in the prior year's period.
- Adjusted EBITDA came in negative at CA$1.4 million, compared to a negative adjusted EBITDA of CA2.4 million in the third quarter of 2022.
- As of Sept. 30, 2023, total assets amounted to CA26.6 million and total liabilities were CA$23.8 million, compared to CA$25.1 million and CA$18.7 million, respectively on Dec. 31, 2022.
- 總收入爲351,688加元（合258,777美元），低於去年同期的475,323加元。
- 總虧損總額爲349,187加元，高於2022年同期的305,850美元。
- 銷售、一般和管理費用總額約爲200萬加元，低於去年同期的340萬加元。
- 該期間的淨虧損總額爲280萬加元，低於去年同期的520萬加元。
- 調整後的息稅折舊攤銷前利潤爲負140萬加元，而2022年第三季度的調整後息稅折舊攤銷前利潤爲負240萬加元。
- 截至2023年9月30日，總資產爲2660萬加元，總負債爲2,380萬加元，而截至2022年12月31日，分別爲2510萬加元和1,870萬加元。
PCLOF Price Action
PCLOF 價格走勢
PharmaCielo's shares traded 6.8453% lower at $0.1311 per share after the market close on Tuesday afternoon.
週二下午市場收盤後，Pharmacielo的股價下跌6.8453％，至每股0.1311美元。
Did you miss the first wave of cannabis investments? Don't make that mistake again.
Experts believe cannabis stocks have found their floor and are now poised for unprecedented growth.
Join Benzinga PotProfits. Our in-house canna stock expert, Michael Berger, is on a mission to uncover the most promising cannabis stocks poised for growth, even in a dull market. He leaves no bud unturned to bring you the juiciest potential double-digit opportunities!
Just this year, the PotProfits portfolio has seen smoking-hot gains like:
你錯過了第一波大麻投資浪潮嗎？別再犯那個錯誤了。
專家認爲，大麻股票已經下跌，現在有望實現前所未有的增長。
加入 Benzinga PotProfit我們的內部大麻股票專家邁克爾·伯傑的使命是發現即使在低迷的市場中也有望增長的最有前途的大麻股票。他不遺餘力地爲你帶來最豐厚的潛在兩位數機會！
就在今年，PotProfits投資組合的漲幅火爆，例如：
- 47.10% with $GTBIF
- 40.23% with $TCNNF
- 21.50% with $VFF
- 47.10% 使用 $GTBIF
- 使用 $TCNNF 獲得 40.23%
- 21.50% 使用 $VFF
But here's the kicker: Michael is about to release his next potential winners, and he's chomping at the bit to share these ticker symbols with you ASAP.Don't miss out on the green rush!
但關鍵在此：邁克爾即將發佈他的下一個潛在贏家，他正在努力盡快與你分享這些股票符號。千萬不要錯過綠色熱潮！
Related News
相關新聞
- PharmaCielo Q2 2023 Results: Revenue Drops But CEO Is Optimistic About Future Growth
- PharmaCielo Q1 2023: Revenue Down 34.2% YoY, CEO Expects Robust Global Sales Of Cannabis Flower In 2023
- PharmaCielo FY 2022 Revenue Grows 173%, What About Adjusted EBITDA?
- PharmaciELO 2023 年第二季度業績：收入下降但首席執行官對未來增長持樂觀態度
- PharmaciELO 2023 年第一季度：收入同比下降34.2％，首席執行官預計 2023 年大麻花的全球銷售將強勁
- PharmaciELO 2022 財年收入增長了 173%，調整後的息稅折舊攤銷前利潤呢？
Photo: Courtesy of Elsa Olofsson on Unsplash
照片：由 Unsplash 上的 Elsa Olofsson 提供